Shares of Insys Therapeutics dropped about 8 percent Monday amid renewed concerns over the pharmaceutical company's sales practices.
NBC News, citing a whistleblower, reported that Subsys — an addictive painkiller 100 times more powerful than morphine used to treat "breakthrough" cancer pain — had been prescribed to patients who shouldn't have received it.
Entering Monday's session, Insys shares had risen more than 53 percent, handily outperforming the iShares Nasdaq Biotechnology ETF (IBB), which had gained about 12 percent.
Insys Therapeutics in 2017
Insys has been the subject of several state and federal investigations over the sales and marketing practices of Subsys since December 2013, according to the firm's latest 10-Q filing.
The filing also showed that two Alabama health-care professionals working with
In a statement released Monday,